ClinicalTrials.gg
CompletedNCT01715298Updated Mar 11, 2015Results posted

NVA237 BID Versus Placebo Twelve-week Efficacy Study

A Phase 3 interventional study of NVA237 and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 59 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2015-03-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
432
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
25th of 73
432 · median 152
Started
2012
with 10 others
Phase 3
33 of 73
1 open now
Registered
30th of 73
by date
Lead sponsor
19 of 73
Novartis Pharmaceuticals

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 25th largest by enrollment, is one of 11 that started in 2012, is one of 33 in phase 3, and was the 30th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe. The efficacy and safety of the drug will be tested against a placebo treatment. The primary criterion to assess efficacy will be the difference between the serial lung function measurements of patients who have been treated for 12 weeks with NVA237 versus those that have received placebo treatment for 12 weeks. A serial lung function measurement (FEV1 testing) will be conducted and the "area under the curve" will be the measure for the ability to breathe.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Anticholinergic
  • Antimuscarinic
  • Chronic Obstructive Airway Disease
  • Chronic Obstructive Lung Disease
  • Chronic Obstructive Pulmonary Disease
  • COPD
  • LAMA
  • Lung Disease
  • Lung Diseases, Obstructive
  • Lung Function
  • Muscarinic receptor antagonist
  • Pulmonary Disease, Chronic Obstructive
  • Respiratory Tract Diseases
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria: 1. Patients with stable, symptomatic (COPD) with airflow obstruction of level 2 and 3 according to the current Global initiative for chronic Obstructive Lung Disease (GOLD) strategy (2011). 2. Patients with (FEV1) ≥ 30% and \<80 % of the predicted normal, and FEV1/FVC \< 0.70 when measured 45 min after the inhalation of 84 µg ipratropium bromide.

  1. Current or ex-smokers with at least 10 cigarette pack years smoking history.

Exclusion criteria:

  1. Patients with a history of long syndrome, with a prolonged QTc measured during screening, or patients who have a abnormality at screening.
  2. History of of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
  3. Pregnant or nursing (lactating) women. Women of unless using an effective method of .
  4. Patients who in the judgment of the investigator, would be at potential risk if enrolled into the study.
  5. Patients who have a clinically significant concomitant disease at screening, including but not limited to clinically significant laboratory abnormalities, clinically significant renal, cardiovascular, neurological, endocrine, immunological, psychiatric, gastrointestinal, hepatic, or hematological abnormalities, or with uncontrolled diabetes, which could interfere with the assessment of the efficacy and safety of the study treatment.
  6. Patients with a (BMI) of more than 40 kg/m2.
  7. Patients for treatment with, or having a history of reactions/ to anticholinergic agents, long and short acting beta-2 agonists, or sympathomimetic amines.
  8. Patients with any history of asthma, with onset of symptoms prior to age 40 years, or patients with a high blood eosinophil count during screening.

Other protocol-defnied inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
432 participants (actual)

Study arms

  • Experimental
    NVA237

    NVA237 will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks

    Drug: NVA237

  • Placebo comparator
    Placebo

    Placebo will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks

    Drug: Placebo

Interventions

  • DrugNVA237

    NVA237 (Glycopyrronioum bromide) as a powder for inhalation in single-dose capsules

  • DrugPlacebo

    Placebo powder for inhalation in single-dose capsules (matching those for NVA237).

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Standardized Area Under the Curve for Forced Expiratory Volume in One Second Post Dosing

    The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) post dosing (FEV1 AUC) is measured at week 12 of treatment. Serial lung function measurements are taken at the following time points following dosing at week 12 to calculate the FEV1 AUC: 5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. The primary endpoint was the change from baseline in FEV1 AUC0-12h following the morning dose at Week 12 (defined as the mean FEV1 change from baseline (CFB) over 5 min to 11 h 55 mins divided by 11 h 50 mins). Where the FEV1 AUC is smaller than at baseline, a negative value can occur

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline in Standardized Area Under the Curve (AUC(0-12h)) for Forced Expiratory Volume in One Second Post Dosing

    The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) post dosing (FEV1 AUC) is assessed at day 1 of treatment. Serial lung function measurements are taken at the following various time points post dosing at day 1 to calculate the FEV1 AUC: 5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. .The endpoint was the change from baseline (CFB) in FEV1 AUC0-12h following the morning dose at day 1 (defined as the mean FEV1 change from baseline over 5 min to 11 h 55 mins divided by 11 h 50 mins). Where the FEV1 AUC is smaller than at baseline, a negative value can occur.

    Time frame: Day 1

  2. Change From Baseline in Standardized Area Under The Curve for Forced Expiratory Volume in One Second for Different Time Spans Post Dosing

    The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1FEV1) is assessed for different time spans (0-4 h, 4-8 h, 8-12 h) within the overall serial measurement post dosing (FEV1 AUCs Time Spans), at day 1 and at week 12 of treatment. Serial lung function measurements are taken at various the following time points post dosing on day 1 and at week 12 to calculate the FEV1 AUC for these different time spans: .5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. The endpoint was the change from baseline (CFB) in FEV1 AUC0-12h following the morning dose at day 1 or week 12, respectively, (defined as the mean FEV1 change from baseline over 5 min to 11 h 55 mins divided by 11 h 50 mins). Where the FEV1 AUC is smaller than at baseline, a negative value can occur.

    Time frame: Day 1 and Week 12

  3. Change From Baseline in Forced Expiratory Volume in One Second at All Individual Timepoints

    The Forced Expiratory Volume in one second (FEV1) assessments for all individual time points of the serial measurements on day 1 and at week 12 are analyzed. Time points of the serial lung function measurements are 5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. The table indicates the percent change from baseline (CFB) in FEV1 and standard deviation in brackets. Where the FEV1 is lower than at baseline, a negative percent value can occur.

    Time frame: Day 1 and week 12

  4. Mean Trough Forced Expiratory Volume in One Second

    Mean trough Forced Expiratory Volume in one second (FEV1) is assessed as the arithmetic mean of two FEV1 measurements, conducted within the last hour of a 24 hour period from a morning dose, either that of day 1 or at week 12 of treatment. The data is reported as the change from baseline (CFB), with the baseline being the arithmetic mean of the two pre-dose measurements (-45 min and -15 min) preceding the serial lung function measurements on Day 1

    Time frame: Day 1 and week 12

  5. Change From Baseline in the Health Status Assessed by St. George's Respiratory Questionnaire

    The health status, as reported by the patients, is assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ is a 50 item scale assessing symptoms, patient activities and impact of the disease. Scores range from 0 to 100 units, with higher scores indicating more limitations. The assessment is based on total score as well as the percentage of patients with clinically significant improvement at week 12 versus day 1. A clinically meaningful improvement (MCID) in SGRQ is defined as a decrease of 4 or more units of the SGRQ scale in the total score, as compared to baseline (change from baseline).

    Time frame: Week 12

  6. Breathlessness Assessed by Transition Dyspnea Index

    Breathlessness at week 12 is measured using the interviewer-administered Transition Dyspnea Index (TDI). On day 1, breathlessness is assessed by the interviewer-administered Baseline Dyspnea Index (BDI). The change from BDI to TDI is assessed, with the TDI total score ranging from -9 to +9 units of the scale. The lower the score, the more deterioration in severity of dyspnea. Patients are considered to have clinically significant improvement (MCID) with the TDI score change versus BDI being equal to or greater than 1.

    Time frame: Week 12

  7. Change From Baseline in Mean Number of Puffs of Rescue Medication Per Day

    Patients report the number of puffs of rescue medication (salbutamol / albuterol) using an electronic diary. The use of rescue medication is analyzed as the change from baseline in the mean daily number of puffs used per patient over the 12 weeks treatment period. The baseline is calculated from the run-in epoch prior to randomization (mean number of puffs per day). A negative number indicates a reduction in the mean daily number of puffs of rescue medication.

    Time frame: Baseline and week 12

  8. Change From Baseline in the Percentage of Days Without Rescue Medication Use

    Patients report the number of puffs of rescue medication (salbutamol / albuterol) using an electronic diary. The use of rescue medication is analyzed as the change from baseline in the percentage of days without usage of rescue medication over the 12 weeks treatment period. The baseline is calculated as the percentage of days without usage of rescue medication from during the the run-in epoch prior to randomization.

    Time frame: Baseline and week 12

  9. Change From Baseline in Daily Symptom Scores

    Patients are reporting symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. Each question can be answered with one of four pre-defined answers, corresponding to a unit value of 0-3, where 0 stands for the lowest and 3 for the most severe symptom experience. Symptom scores are calculated as the mean of the combined daily symptom scores (combined from morning and evening scores) for each patient over 12 weeks (Day 1 to week 12). The baseline is calculated from the run-in epoch prior to randomization. The change from baseline in the least squares mean daily symptom scores over the 12 week treatment period is provided. Where the mean daily symptom score over the 12 week treatment period is lower than the baseline, the result is negative. A negative result indicates an improvement in COPD symptom severity.

    Time frame: day 1 to week 12

  10. Change From Baseline in the Percentage of Nights With "no Nighttime Awakenings"

    Patients are reporting symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. One of the symptom questions of the morning questionnaire relates to the number of awakenings due to COPD symptoms during the previous night. The answer with the lowest symptom score is "no waking due to symptoms." A night with "no nighttime awakening" is defined from diary data as any night where the patient did not wake up due to symptoms. The change from baseline in the percentage of nights with "no nighttime awakening" is calculated from the mean percentage of nights with this answer over the 12 week treatment period, with the baseline being The baseline is calculated from the run-in epoch prior to randomization.

    Time frame: Day 1 and week 12

  11. Change From Baseline in the Percentage of Days With "no Daytime Symptoms"

    Patients are reporting symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. Each question can be answered with one of four pre-defined answers, corresponding to a unit value of 0-3, where 0 stands for the lowest and 3 for the most severe symptom experience. A day with "no daytime symptoms" is defined from diary data as any day where the patient has recorded in the evening no cough, no wheeze, no production of sputum, and no feeling of breathlessness (other than when running) during the past approximately 12 hours in the evening questionnaire. The change from baseline in the percentage of days with "no daytime symptoms" is calculated from the mean percentage of days with this answer over the 12 week treatment period, with the baseline being. The baseline is calculated from the run-in epoch prior to randomization.

    Time frame: Day 1 to week 12

  12. Change From Baseline in Percentage of "Days Able to Perform Usual Daily Activities"

    Patients are reporting symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. One of the symptom questions of the evening questionnaire relates to the impact of COPD symptoms on the performance of usual daily activities ("Did your respiratory symptoms stop you performing your usual daily activities today"). The answer with the lowest symptom score is "not at all." A "day able to perform usual daily activities" is defined from diary data as any day where the patient was not prevented from performing their usual daily activities due to respiratory symptoms. The change from baseline in the percentage of "days able to perform usual daily activities" is calculated from the mean percentage of days with this answer over the 12 week treatment period, with the baseline beingThe baseline is calculated from the run-in epoch prior to randomization.

    Time frame: Day 1 to week 12

  13. Change From Baseline in Forced Vital Capacity at All Individual Timepoints

    The Forced Vital Capacity (FVC)assessments for all individual time points of the serial measurements on day 1 and at week 12 are analyzed. Serial lung function measurements are taken at the following time points following dosing on Day 1 and at week 12: 5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. For week 12 (day 85), the pre-dose measurements (-45 min and -15 min) and the trough measurements (23:15 h and 23:45 h post-dose) are included. The endpoints are the change from baseline in FVC following the morning dose on Day 1 and at Week 12. Where the FVC at any one timepoint is smaller than at baseline, a negative value can occur.

    Time frame: Day 1 and week 12

  14. Change From Baseline in Mean Trough Forced Vital Capacity

    Mean trough Forced Vital Capacity (FVC) is assessed as the arithmetic mean of two FVC measurements, conducted within the last hour of a 24 hours period from a morning dose, either that of day 1 or at week 12 of treatment (23:15 h and 23:45 h assessments). The endpoints are the change from baseline in trough FVC on Day 1 and at Week 12, with the mean of the -45 min and -15 min measurements on Day 1 as the baseline.

    Time frame: Day 1 and week 12

  15. Change From Baseline in Morning and Nighttime Symptom Scores

    Patients are reporting morning and nighttime symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. Each question can be answered with one of four pre-defined answers, corresponding to a unit value of 0-3, where 0 stands for the lowest and 3 for the most severe symptom experience. Morning and nighttime symptoms scores for each patient over 12 weeks are reported and analyzed. Symptom scores are calculated as the mean of the symptom scores (morning symptom scores or nighttime symptom scores, respectively) for each patient over 12 weeks (Day 1 to week 12). The baseline is calculated from the run-in epoch prior to randomization. The outcome is calculated as the change from baseline in the morning and nighttime symptom scores, respectively. A negative number indicates a reduction in the symptom severity and is owed to the calculation of the change from baseline.

    Time frame: Day 1 to week 12

07

Results

Posted Mar 11, 2015

Participant flow

Participant flow — Overall Study
MilestoneNVA237Placebo
Started216216
Full analysis set (fas)215214
Completed209205
Not completed711
Withdrew: Lost to follow-up02
Withdrew: Patient/guardian decision79

Outcome measures

PrimaryChange From Baseline in Standardized Area Under the Curve for Forced Expiratory Volume in One Second Post Dosing

The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) post dosing (FEV1 AUC) is measured at week 12 of treatment. Serial lung function measurements are taken at the following time points following dosing at week 12 to calculate the FEV1 AUC: 5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. The primary endpoint was the change from baseline in FEV1 AUC0-12h following the morning dose at Week 12 (defined as the mean FEV1 change from baseline (CFB) over 5 min to 11 h 55 mins divided by 11 h 50 mins). Where the FEV1 AUC is smaller than at baseline, a negative value can occur

Time frame:
Week 12
Reported as:
Least squares mean · Liters
Change From Baseline in Standardized Area Under the Curve for Forced Expiratory Volume in One Second Post Dosing
LitersNVA237Placebo
Change From Baseline in Standardized Area Under the Curve for Forced Expiratory Volume in One Second Post Dosing0.115 ± 0.0153-0.008 ± 0.0153
SecondaryChange From Baseline in Standardized Area Under the Curve (AUC(0-12h)) for Forced Expiratory Volume in One Second Post Dosing

The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) post dosing (FEV1 AUC) is assessed at day 1 of treatment. Serial lung function measurements are taken at the following various time points post dosing at day 1 to calculate the FEV1 AUC: 5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. .The endpoint was the change from baseline (CFB) in FEV1 AUC0-12h following the morning dose at day 1 (defined as the mean FEV1 change from baseline over 5 min to 11 h 55 mins divided by 11 h 50 mins). Where the FEV1 AUC is smaller than at baseline, a negative value can occur.

Time frame:
Day 1
Reported as:
Least squares mean · Liters
Change From Baseline in Standardized Area Under the Curve (AUC(0-12h)) for Forced Expiratory Volume in One Second Post Dosing
LitersNVA237Placebo
Change From Baseline in Standardized Area Under the Curve (AUC(0-12h)) for Forced Expiratory Volume in One Second Post Dosing0.121 ± 0.00960.003 ± 0.0096
SecondaryChange From Baseline in Standardized Area Under The Curve for Forced Expiratory Volume in One Second for Different Time Spans Post Dosing

The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1FEV1) is assessed for different time spans (0-4 h, 4-8 h, 8-12 h) within the overall serial measurement post dosing (FEV1 AUCs Time Spans), at day 1 and at week 12 of treatment. Serial lung function measurements are taken at various the following time points post dosing on day 1 and at week 12 to calculate the FEV1 AUC for these different time spans: .5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. The endpoint was the change from baseline (CFB) in FEV1 AUC0-12h following the morning dose at day 1 or week 12, respectively, (defined as the mean FEV1 change from baseline over 5 min to 11 h 55 mins divided by 11 h 50 mins). Where the FEV1 AUC is smaller than at baseline, a negative value can occur.

Time frame:
Day 1 and Week 12
Reported as:
Least squares mean · Liters
Change From Baseline in Standardized Area Under The Curve for Forced Expiratory Volume in One Second for Different Time Spans Post Dosing
LitersNVA237Placebo
Day 1 AUC 0-4h (n=215,213)0.154 ± 0.00880.014 ± 0.0088
Week 12 AUC 0-4h (n=215,213)0.153 ± 0.01590.004 ± 0.0159
Day 1 AUC 4-8h (n=213,209)0.118 ± 0.01070.011 ± 0.0109
Week 12 AUC 4-8h (n=213,209)0.107 ± 0.01590.000 ± 0.0158
Day 1 AUC 8-12h (n=212,210)0.085 ± 0.0120-0.021 ± 0.0120
Week 12 AUC 8-12h (n=212,210)0.075 ± 0.0164-0.033 ± 0.0164
SecondaryChange From Baseline in Forced Expiratory Volume in One Second at All Individual Timepoints

The Forced Expiratory Volume in one second (FEV1) assessments for all individual time points of the serial measurements on day 1 and at week 12 are analyzed. Time points of the serial lung function measurements are 5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. The table indicates the percent change from baseline (CFB) in FEV1 and standard deviation in brackets. Where the FEV1 is lower than at baseline, a negative percent value can occur.

Time frame:
Day 1 and week 12
Reported as:
Mean · Percent
Change From Baseline in Forced Expiratory Volume in One Second at All Individual Timepoints
PercentNVA237Placebo
FEV1, day 1, 5 min (n=207,202)4.9 ± 8.67-0.3 ± 7.07
FEV1, day 1, 15 min (n=209,201)9.9 ± 10.050.3 ± 7.62
FEV1, day 1, 1 h (n=205,205)13.9 ± 11.981.2 ± 9.05
FEV1, day 1, 2 h (n=201,205)16.0 ± 14.422.5 ± 9.80
FEV1, day 1, 4 h (n=199,202)12.7 ± 13.392.2 ± 12.63
FEV1, day 1, 6h (n=197,197)10.3 ± 13.822.2 ± 11.88
FEV1, day 1, 8 h (n=200,189)8.9 ± 14.43-0.5 ± 12.42
FEV1, day 1, 11 h 55min (n=184,182)6.6 ± 13.44-1.7 ± 14.03
FEV1, day 85, -45min (n=184,188)6.4 ± 17.611.7 ± 17.95
FEV1, day 85, -15min (n=180,185)9.6 ± 18.232.7 ± 17.82
FEV1, day 85, 5min (n=185,178)10.4 ± 18.781.8 ± 17.22
FEV1, day 85, 15min (n=186,189)12.9 ± 20.002.0 ± 17.08
FEV1, day 85, 1h (n=184,187)15.8 ± 20.491.6 ± 17.37
FEV1, day 85, 2h (n=178,187)16.0 ± 20.832.4 ± 18.52
FEV1, day 85, 4h (n=179,183)12.5 ± 19.723.5 ± 20.25
FEV1, day 85, 6h (n=174,172)9.8 ± 18.782.5 ± 20.84
FEV1, day 85, 8h (n=178,174)7.8 ± 18.180.2 ± 18.86
FEV1, day 85, 11h 55min (n=171,171)7.2 ± 19.39-2.1 ± 20.07
SecondaryMean Trough Forced Expiratory Volume in One Second

Mean trough Forced Expiratory Volume in one second (FEV1) is assessed as the arithmetic mean of two FEV1 measurements, conducted within the last hour of a 24 hour period from a morning dose, either that of day 1 or at week 12 of treatment. The data is reported as the change from baseline (CFB), with the baseline being the arithmetic mean of the two pre-dose measurements (-45 min and -15 min) preceding the serial lung function measurements on Day 1

Time frame:
Day 1 and week 12
Reported as:
Least squares mean · Liters
Mean Trough Forced Expiratory Volume in One Second
LitersNVA237Placebo
Day 10.128 ± 0.01290.021 ± 0.0130
Week 120.123 ± 0.01660.038 ± 0.0166
SecondaryChange From Baseline in the Health Status Assessed by St. George's Respiratory Questionnaire

The health status, as reported by the patients, is assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ is a 50 item scale assessing symptoms, patient activities and impact of the disease. Scores range from 0 to 100 units, with higher scores indicating more limitations. The assessment is based on total score as well as the percentage of patients with clinically significant improvement at week 12 versus day 1. A clinically meaningful improvement (MCID) in SGRQ is defined as a decrease of 4 or more units of the SGRQ scale in the total score, as compared to baseline (change from baseline).

Time frame:
Week 12
Reported as:
Least squares mean · Score
Change From Baseline in the Health Status Assessed by St. George's Respiratory Questionnaire
ScoreNVA237Placebo
Change From Baseline in the Health Status Assessed by St. George's Respiratory Questionnaire-6.4 ± 1.08-1.2 ± 1.06
SecondaryBreathlessness Assessed by Transition Dyspnea Index

Breathlessness at week 12 is measured using the interviewer-administered Transition Dyspnea Index (TDI). On day 1, breathlessness is assessed by the interviewer-administered Baseline Dyspnea Index (BDI). The change from BDI to TDI is assessed, with the TDI total score ranging from -9 to +9 units of the scale. The lower the score, the more deterioration in severity of dyspnea. Patients are considered to have clinically significant improvement (MCID) with the TDI score change versus BDI being equal to or greater than 1.

Time frame:
Week 12
Reported as:
Least squares mean · Score
Breathlessness Assessed by Transition Dyspnea Index
ScoreNVA237Placebo
Breathlessness Assessed by Transition Dyspnea Index0.95 ± 0.2800.48 ± 0.277
SecondaryChange From Baseline in Mean Number of Puffs of Rescue Medication Per Day

Patients report the number of puffs of rescue medication (salbutamol / albuterol) using an electronic diary. The use of rescue medication is analyzed as the change from baseline in the mean daily number of puffs used per patient over the 12 weeks treatment period. The baseline is calculated from the run-in epoch prior to randomization (mean number of puffs per day). A negative number indicates a reduction in the mean daily number of puffs of rescue medication.

Time frame:
Baseline and week 12
Reported as:
Least squares mean · Number of puffs
Change From Baseline in Mean Number of Puffs of Rescue Medication Per Day
Number of puffsNVA237Placebo
Change From Baseline in Mean Number of Puffs of Rescue Medication Per Day-1.33 ± 0.163-0.80 ± 0.160
SecondaryChange From Baseline in the Percentage of Days Without Rescue Medication Use

Patients report the number of puffs of rescue medication (salbutamol / albuterol) using an electronic diary. The use of rescue medication is analyzed as the change from baseline in the percentage of days without usage of rescue medication over the 12 weeks treatment period. The baseline is calculated as the percentage of days without usage of rescue medication from during the the run-in epoch prior to randomization.

Time frame:
Baseline and week 12
Reported as:
Least squares mean · percentage of days
Change From Baseline in the Percentage of Days Without Rescue Medication Use
percentage of daysNVA237Placebo
Change From Baseline in the Percentage of Days Without Rescue Medication Use11.4 ± 1.957.0 ± 1.97
SecondaryChange From Baseline in Daily Symptom Scores

Patients are reporting symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. Each question can be answered with one of four pre-defined answers, corresponding to a unit value of 0-3, where 0 stands for the lowest and 3 for the most severe symptom experience. Symptom scores are calculated as the mean of the combined daily symptom scores (combined from morning and evening scores) for each patient over 12 weeks (Day 1 to week 12). The baseline is calculated from the run-in epoch prior to randomization. The change from baseline in the least squares mean daily symptom scores over the 12 week treatment period is provided. Where the mean daily symptom score over the 12 week treatment period is lower than the baseline, the result is negative. A negative result indicates an improvement in COPD symptom severity.

Time frame:
day 1 to week 12
Reported as:
Least squares mean · Score
Change From Baseline in Daily Symptom Scores
ScoreNVA237Placebo
Change From Baseline in Daily Symptom Scores-1.09 ± 0.103-0.80 ± 0.104
SecondaryChange From Baseline in the Percentage of Nights With "no Nighttime Awakenings"

Patients are reporting symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. One of the symptom questions of the morning questionnaire relates to the number of awakenings due to COPD symptoms during the previous night. The answer with the lowest symptom score is "no waking due to symptoms." A night with "no nighttime awakening" is defined from diary data as any night where the patient did not wake up due to symptoms. The change from baseline in the percentage of nights with "no nighttime awakening" is calculated from the mean percentage of nights with this answer over the 12 week treatment period, with the baseline being The baseline is calculated from the run-in epoch prior to randomization.

Time frame:
Day 1 and week 12
Reported as:
Least squares mean · Percentage of nights
Change From Baseline in the Percentage of Nights With "no Nighttime Awakenings"
Percentage of nightsNVA237Placebo
Change From Baseline in the Percentage of Nights With "no Nighttime Awakenings"13.1 ± 1.529.2 ± 1.54
SecondaryChange From Baseline in the Percentage of Days With "no Daytime Symptoms"

Patients are reporting symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. Each question can be answered with one of four pre-defined answers, corresponding to a unit value of 0-3, where 0 stands for the lowest and 3 for the most severe symptom experience. A day with "no daytime symptoms" is defined from diary data as any day where the patient has recorded in the evening no cough, no wheeze, no production of sputum, and no feeling of breathlessness (other than when running) during the past approximately 12 hours in the evening questionnaire. The change from baseline in the percentage of days with "no daytime symptoms" is calculated from the mean percentage of days with this answer over the 12 week treatment period, with the baseline being. The baseline is calculated from the run-in epoch prior to randomization.

Time frame:
Day 1 to week 12
Reported as:
Least squares mean · Percentage of days
Change From Baseline in the Percentage of Days With "no Daytime Symptoms"
Percentage of daysNVA237Placebo
Change From Baseline in the Percentage of Days With "no Daytime Symptoms"3.6 ± 1.172.6 ± 1.18
SecondaryChange From Baseline in Percentage of "Days Able to Perform Usual Daily Activities"

Patients are reporting symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. One of the symptom questions of the evening questionnaire relates to the impact of COPD symptoms on the performance of usual daily activities ("Did your respiratory symptoms stop you performing your usual daily activities today"). The answer with the lowest symptom score is "not at all." A "day able to perform usual daily activities" is defined from diary data as any day where the patient was not prevented from performing their usual daily activities due to respiratory symptoms. The change from baseline in the percentage of "days able to perform usual daily activities" is calculated from the mean percentage of days with this answer over the 12 week treatment period, with the baseline beingThe baseline is calculated from the run-in epoch prior to randomization.

Time frame:
Day 1 to week 12
Reported as:
Least squares mean · Percentage of days
Change From Baseline in Percentage of "Days Able to Perform Usual Daily Activities"
Percentage of daysNVA237Placebo
Change From Baseline in Percentage of "Days Able to Perform Usual Daily Activities"5.2 ± 1.610.9 ± 1.65
SecondaryChange From Baseline in Forced Vital Capacity at All Individual Timepoints

The Forced Vital Capacity (FVC)assessments for all individual time points of the serial measurements on day 1 and at week 12 are analyzed. Serial lung function measurements are taken at the following time points following dosing on Day 1 and at week 12: 5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. For week 12 (day 85), the pre-dose measurements (-45 min and -15 min) and the trough measurements (23:15 h and 23:45 h post-dose) are included. The endpoints are the change from baseline in FVC following the morning dose on Day 1 and at Week 12. Where the FVC at any one timepoint is smaller than at baseline, a negative value can occur.

Time frame:
Day 1 and week 12
Reported as:
Least squares mean · Liters
Change From Baseline in Forced Vital Capacity at All Individual Timepoints
LitersNVA237Placebo
FVC, day 1, 5 min (n=214,211)0.120 ± 0.0129-0.014 ± 0.0131
FVC, day 1, 15 min (n=214,213)0.233 ± 0.01550.005 ± 0.0157
FVC, day 1, 1 h (n=215,211)0.304 ± 0.01750.041 ± 0.0176
FVC, day 1, 2 h (n=211,211)0.322 ± 0.01930.060 ± 0.0191
FVC, day 1, 4 h (n=209,208)0.247 ± 0.01960.048 ± 0.0195
FVC, day 1, 6 h (n=208,205)0.225 ± 0.02190.051 ± 0.0220
FVC, day 1, 8 h (n=209,205)0.200 ± 0.0228-0.002 ± 0.0232
FVC, day 1, 11 h 55min (n=203,202)0.147 ± 0.0242-0.017 ± 0.0243
FVC, day 85, -45 min (n=207,204)0.123 ± 0.02480.008 ± 0.0246
FVC, day 85, -15 min (n=208,204)0.146 ± 0.02410.010 ± 0.0239
FVC, day 85, 5 min (n=214,211)0.177 ± 0.02470.001 ± 0.0251
FVC, day 85, 15 min (n=214,213)0.219 ± 0.0261-0.003 ± 0.0259
FVC, day 85, 1 hr (n=215,211)0.267 ± 0.02610.010 ± 0.0260
FVC, day 85, 2 hr (n=211,211)0.275 ± 0.02770.024 ± 0.0271
FVC, day 85, 4 hr (n=209,208)0.204 ± 0.02810.035 ± 0.0278
FVC, day 85, 6 hr (n=208,205)0.185 ± 0.02780.016 ± 0.0278
FVC, day 85, 8 hr (n=209,205)0.152 ± 0.0264-0.015 ± 0.0266
FVC, day 85, 11 hr 55min (n=203,202)0.135 ± 0.0290-0.045 ± 0.0288
FVC, day 85, 23 hr 15min (n=210,204)0.207 ± 0.02890.066 ± 0.0284
FVC, day 85, 23 hr 45min (n=213,208)0.228 ± 0.02920.095 ± 0.0290
SecondaryChange From Baseline in Mean Trough Forced Vital Capacity

Mean trough Forced Vital Capacity (FVC) is assessed as the arithmetic mean of two FVC measurements, conducted within the last hour of a 24 hours period from a morning dose, either that of day 1 or at week 12 of treatment (23:15 h and 23:45 h assessments). The endpoints are the change from baseline in trough FVC on Day 1 and at Week 12, with the mean of the -45 min and -15 min measurements on Day 1 as the baseline.

Time frame:
Day 1 and week 12
Reported as:
Least squares mean · Liters
Change From Baseline in Mean Trough Forced Vital Capacity
LitersNVA237Placebo
Day 10.249 ± 0.02250.078 ± 0.0227
Week 120.210 ± 0.02770.080 ± 0.0276
SecondaryChange From Baseline in Morning and Nighttime Symptom Scores

Patients are reporting morning and nighttime symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. Each question can be answered with one of four pre-defined answers, corresponding to a unit value of 0-3, where 0 stands for the lowest and 3 for the most severe symptom experience. Morning and nighttime symptoms scores for each patient over 12 weeks are reported and analyzed. Symptom scores are calculated as the mean of the symptom scores (morning symptom scores or nighttime symptom scores, respectively) for each patient over 12 weeks (Day 1 to week 12). The baseline is calculated from the run-in epoch prior to randomization. The outcome is calculated as the change from baseline in the morning and nighttime symptom scores, respectively. A negative number indicates a reduction in the symptom severity and is owed to the calculation of the change from baseline.

Time frame:
Day 1 to week 12
Reported as:
Least squares mean · Score
Change From Baseline in Morning and Nighttime Symptom Scores
ScoreNVA237Placebo
Daytime total symptom score (n=207,195)-0.86 ± 0.097-0.61 ± 0.100
Nighttime total symptom score (n=208,200)-1.03 ± 0.101-0.76 ± 0.102

Adverse events

Non-serious events are listed at a 0.9% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NVA237—9/216 (4.2%)88/216 (40.7%)
Placebo—5/214 (2.3%)81/214 (37.9%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventNVA237Placebo
CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders3/2163/214
SPINAL COMPRESSION FRACTUREInjury, poisoning and procedural complications0/2161/214
HAEMOPTYSISRespiratory, thoracic and mediastinal disorders0/2161/214
PULMONARY MASSRespiratory, thoracic and mediastinal disorders0/2161/214
ACUTE MYOCARDIAL INFARCTIONCardiac disorders1/2160/214
ANGINA PECTORISCardiac disorders1/2160/214
CELLULITISInfections and infestations1/2160/214
HERPES SIMPLEXInfections and infestations1/2160/214
OPHTHALMIC HERPES ZOSTERInfections and infestations1/2160/214
PNEUMONIAInfections and infestations1/2160/214
Most frequent other events
Showing 10 of 40
Most frequent other events
EventNVA237Placebo
CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders43/21643/214
HEADACHENervous system disorders2/2167/214
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations7/2163/214
COUGHRespiratory, thoracic and mediastinal disorders6/2166/214
NASAL CONGESTIONRespiratory, thoracic and mediastinal disorders0/2165/214
NASOPHARYNGITISInfections and infestations5/2162/214
BACK PAINMusculoskeletal and connective tissue disorders5/2161/214
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders5/2161/214
BRONCHITISInfections and infestations0/2164/214
DIARRHOEAGastrointestinal disorders2/2163/214

Baseline characteristics

Age, Continuous
Age, Continuous(Years)NVA237PlaceboTotal
Mean63.9 ± 8.5564.2 ± 8.4164.1 ± 8.47
Sex: Female, Male
Sex: Female, Male(Participants)NVA237PlaceboTotal
Female8890178
Male128126254
08

Study locations

59 sites
  • Novartis Investigative Site
    *See Various Dept.'s*, Arizona, United States
  • Novartis Investigative Site
    Chandler, Arizona 85224, United States
  • Novartis Investigative Site
    Fresno, California 93726, United States
  • Novartis Investigative Site
    Fullerton, California 92835, United States
  • Novartis Investigative Site
    Yorba Linda, California 92886-7921, United States
  • Novartis Investigative Site
    Yorba Linda, California 92886, United States
  • Novartis Investigative Site
    Boulder, Colorado 80304, United States
  • Novartis Investigative Site
    Wheat Ridge, Colorado 80033, United States
  • Novartis Investigative Site
    Lynn Haven, Florida 32444, United States
  • Novartis Investigative Site
    Miami, Florida 33173, United States
  • Novartis Investigative Site
    Port Orange, Florida 32127, United States
  • Novartis Investigative Site
    Winter Park, Florida 32789, United States
  • Novartis Investigative Site
    Conyers, Georgia 30094, United States
  • Novartis Investigative Site
    River Forest, Illinois 60305, United States
  • Novartis Investigative Site
    Skokie, Illinois 60076, United States
  • Novartis Investigative Site
    Evansville, Indiana 47714, United States
  • Novartis Investigative Site
    Lexington, Kentucky 40509, United States
  • Novartis Investigative Site
    Sunset, Louisiana 70584, United States
  • Novartis Investigative Site
    Fall River, Massachusetts 02720, United States
  • Novartis Investigative Site
    North Dartmouth, Massachusetts 02747, United States
  • Novartis Investigative Site
    Minneapolis, Minnesota 55402, United States
  • Novartis Investigative Site
    Plymouth, Minnesota 55441, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63128, United States
  • Novartis Investigative Site
    St. Charles, Missouri 63301, United States
  • Novartis Investigative Site
    St. Louis, Missouri 63141, United States
  • Novartis Investigative Site
    Fremont, Nebraska 68025, United States
  • Novartis Investigative Site
    Lincoln, Nebraska 68510, United States
  • Novartis Investigative Site
    Omaha, Nebraska 68114, United States
  • Novartis Investigative Site
    Cherry Hill, New Jersey 08003, United States
  • Novartis Investigative Site
    Albuquerque, New Mexico 87108, United States
  • Novartis Investigative Site
    Brooklyn, New York 11229, United States
  • Novartis Investigative Site
    Brooklyn, New York 11234, United States
  • Novartis Investigative Site
    Great Neck, New York 11021, United States
  • Novartis Investigative Site
    Massapequa, New York 11758, United States
  • Novartis Investigative Site
    New Windsor, New York 12553, United States
  • Novartis Investigative Site
    New York, New York 10003, United States
  • Novartis Investigative Site
    New York, New York 10028, United States
  • Novartis Investigative Site
    Charlotte, North Carolina 28207, United States
  • Novartis Investigative Site
    Cincinnati, Ohio 45231, United States
  • Novartis Investigative Site
    Cincinnati, Ohio 45242, United States
  • Novartis Investigative Site
    Cincinnati, Ohio 45245, United States
  • Novartis Investigative Site
    Columbus, Ohio 43213, United States
  • Novartis Investigative Site
    Medford, Oregon 97504-8741, United States
  • Novartis Investigative Site
    Medford, Oregon 97504, United States
  • Novartis Investigative Site
    Portland, Oregon 97213, United States
  • Novartis Investigative Site
    Langhorne, Pennsylvania 19047, United States
  • Novartis Investigative Site
    Pittsburgh, Pennsylvania 15243, United States
  • Novartis Investigative Site
    Pottstown, Pennsylvania 19464, United States
  • Novartis Investigative Site
    Tipton, Pennsylvania 16684, United States
  • Novartis Investigative Site
    East Providence, Rhode Island 02914, United States
  • Novartis Investigative Site
    Fort Mill, South Carolina 29707, United States
  • Novartis Investigative Site
    Rock Hll, South Carolina 29732, United States
  • Novartis Investigative Site
    Denton, Texas 76210, United States
  • Novartis Investigative Site
    San Antonio, Texas 78229, United States
  • Novartis Investigative Site
    Midvale, Utah 84047, United States
  • Novartis Investigative Site
    South Burlington, Vermont 05403, United States
  • Novartis Investigative Site
    Richmond, Virginia 23219, United States
  • Novartis Investigative Site
    Richmond, Virginia 23233, United States
  • Novartis Investigative Site
    Tacoma, Washington 98405, United States
09

References and documents

Publications

  • Kerwin E, Siler TM, Korenblat P, White A, Eckert JH, Henley M, Patalano F, D'Andrea P. Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study. Chronic Obstr Pulm Dis. 2016 Mar 28;3(2):549-559. doi: 10.15326/jcopdf.3.2.2015.0157. PubMed 28848879 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2012
First posted
Oct 26, 2012
Start
Nov 2012
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
Mar 11, 2015
Last update
Mar 11, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01715298
Responsible party
Sponsor
First posted
Oct 26, 2012
Start date
Nov 2012
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Mar 11, 2015
Last update
Mar 11, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion